scholarly journals Self-Reported Sleep Apnea and Dementia Risk: Findings from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Trial

2016 ◽  
Vol 64 (12) ◽  
pp. 2472-2478 ◽  
Author(s):  
Xiuhua Ding ◽  
Richard J. Kryscio ◽  
Joshua Turner ◽  
Gregory A. Jicha ◽  
Gregory Cooper ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vitamin E ◽  
Sleep Apnea ◽  
Dementia Risk

scholarly journals DIABETES MITIGATES THE ROLE OF MEMORY COMPLAINT IN PREDICTING DEMENTIA RISK: RESULTS FROM THE PREVENTION OF ALZHEIMER’S DISEASE WITH VITAMIN E AND SELENIUM STUDY

2017 ◽  
pp. 1-6
Author(s):  
X. Zhang ◽  
F.A. Schmitt ◽  
A.M. Caban-Holt ◽  
X. Ding ◽  
R.J. Kryscio ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vitamin E ◽  
Cancer Prevention ◽  
Black Men ◽  
Bypass Graft ◽  
Prevention Trial ◽  
Dementia Risk ◽  
Increased Risk

Background: Subjective memory complaints (SMCs) are associated with increased risk of dementia in older adults, but the role of comorbidities in modifying this risk is unknown. Objectives: To assess whether comorbidities modify estimated dementia risk based on SMCs. Design: The Prevention of Alzheimer’s Disease with Vitamin E and Selenium Study (PREADVISE) was designed as an ancillary study to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized, multi-center prostate cancer prevention trial with sites in the Unites States, Puerto Rico, and Canada. In 2009, PREADVISE and SELECT were changed into cohort studies. Setting: Secondary analysis of PREADVISE data. Participants: PREADVISE recruited 7,540 non-demented male volunteers from participating SELECT sites from 2002 to 2009. SMCs, demographics, and comorbidities including hypertension, diabetes, coronary artery bypass graft (CABG), stroke, sleep apnea, and head injury were ascertained by participant interview. Measurements: Cox models were used to investigate whether baseline comorbidities modified hazard ratios (HR) for SMC-associated dementia risk using two methods: (1) we included one interaction term between SMC and a comorbidity in the model at a time, and (2) we included all two-way interactions between SMC and covariates of interest and reduced the model by “backward” selection. SMC was operationalized as any complaint vs. no complaint. Results: Baseline SMCs were common (23.6%). In the first analyses, with the exception of stroke, presence of self-reported comorbidities was associated with lower estimated HR for dementia based on SMC status (complaint vs. no complaint), but this difference was only significant for diabetes. In the second analysis, the two-way interactions between SMC and race as well as SMC and diabetes were significant. Here, black men without diabetes who reported SMC had the highest estimated dementia risk (HR=5.05, 95% CI 2.55-10.00), while non-black men with diabetes who reported SMC had the lowest estimated risk (HR=0.71, 95% CI 0.35-1.41). Conclusions: SMCs were more common among men with comorbidities, but these complaints appeared to be less predictive of dementia risk than those originating from men without comorbidities, suggesting that medical conditions such as diabetes may explain SMCs that are unrelated to an underlying neurodegenerative process.

scholarly journals Obstructive sleep apnea, cognition and Alzheimer's disease: A systematic review integrating three decades of multidisciplinary research

2020 ◽  
Vol 50 ◽  
pp. 101250 ◽  
Author(s):  
Omonigho M. Bubu ◽  
Andreia G. Andrade ◽  
Ogie Q. Umasabor-Bubu ◽  
Megan M. Hogan ◽  
Arlener D. Turner ◽  
...  
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Multidisciplinary Research ◽  
Obstructive Sleep

scholarly journals The role of sleep apnea in APOE‐Alzheimer's disease pathway

2020 ◽  
Vol 16 (S10) ◽  
Author(s):  
Krupa N Hegde ◽  
Xiuhua Ding ◽  
Marylin Gardner
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Sleep Apnea

Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease

1997 ◽  
Vol 104 (6-7) ◽  
pp. 703-710 ◽  
Author(s):  
F. J. Jiménez-Jiménez ◽  
F. de Bustos ◽  
J. A. Molina ◽  
J. Benito-León ◽  
A. Tallón-Barranco ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Vitamin E ◽  
Alpha Tocopherol ◽  
Cerebrospinal Fluid Levels ◽  
Fluid Levels

scholarly journals Antioxidant strategies for Alzheimer's disease

2002 ◽  
Vol 61 (2) ◽  
pp. 191-202 ◽  
Author(s):  
Michael Grundman ◽  
Patrick Delaney
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vitamin E ◽  
Oxidative Damage ◽  
Functional Decline ◽  
Antioxidant Properties ◽  
Epidemiological Studies ◽  
Clinical Value ◽  
Antioxidant Defences ◽  
Ad Prevention

Oxidative damage is present within the brains of patients with Alzheimer's disease (AD), and is observed within every class of biomolecule, including nucleic acids, proteins, lipids and carbohydrates. Oxidative injury may develop secondary to excessive oxidative stress resulting from β-amyloid-induced free radicals, mitochondrial abnormalities, inadequate energy supply, inflammation or altered antioxidant defences. Treatment with antioxidants is a promising approach for slowing disease progression to the extent that oxidative damage may be responsible for the cognitive and functional decline observed in AD. Although not a uniformly consistent observation, a number of epidemiological studies have found a link between antioxidant intake and a reduced incidence of dementia, AD and cognitive decline in elderly populations. In AD clinical trials molecules with antioxidant properties such as vitamin E andGinkgo bilobaextract have shown modest benefit. A clinical trial with vitamin E is currently ongoing to determine if it can delay progression to AD in individuals with mild cognitive impairment. Combinations of antioxidants might be of even greater potential benefit for AD, especially if the agents worked in different cellular compartments or had complementary activity (e.g. vitamins E, C and ubiquinone). Naturally-occurring compounds with antioxidant capacity are available and widely marketed (e.g. vitamin C, ubiquinone, lipoic acid, β-carotene, creatine, melatonin, curcumin) and synthetic compounds are under development by industry. Nevertheless, the clinical value of these agents for AD prevention and treatment is ambiguous, and will remain so until properly designed human trials have been performed.

Self‐reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time‐dependent progression

2020 ◽  
Author(s):  
Omonigho M. Bubu ◽  
Ogie Q. Umasabor‐Bubu ◽  
Arlener D Turner ◽  
Ankit Parekh ◽  
Anna E. Mullins ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Time Dependent ◽  
Obstructive Sleep

Effects of sleep architecture and sleep apnea on Alzheimer's disease biomarkers in cognitively normal elderly

2017 ◽  
Vol 40 ◽  
pp. e336-e337
Author(s):  
A.W. Varga ◽  
K. Kam ◽  
R. Sharma ◽  
A. Parekh ◽  
B. Castillo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Sleep Apnea ◽  
Sleep Architecture ◽  
Cognitively Normal ◽  
Disease Biomarkers
Sign in / Sign up

Export Citation Format

Share Document